Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT07535606
PHASE1
A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
Sponsor: Alnylam Pharmaceuticals
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.
Official title: A Phase 1, Randomized, Double-Masked, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-4915 in Adult Healthy Volunteers
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
44
Start Date
2026-03-02
Completion Date
2027-07-31
Last Updated
2026-04-17
Healthy Volunteers
Yes
Conditions
Interventions
DRUG
ALN-4915
ALN-4915 will be administered subcutaneously (SC)
DRUG
Placebo
Placebo will be administered SC
Locations (1)
Clinical Trial Site
London, United Kingdom